Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB +2.36%54 Capex-to-Operating-Income is 1.35 as of Dec. 2025, which is 18% below its 10-year median of 1.65. GuruFocus rates XMAD:LAB with a GF Score™ of 54/100 and a GF Value™ of €3.62 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 506 Drug Manufacturers companies, Labiana Health ranks worse than 65.42% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Labiana Health (XMAD:LAB) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Labiana Health Capex-to-Operating-Income Related Terms
Labiana Health Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Labiana Health's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Capex-to-Operating-Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Capex-to-Operating-Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Labiana Health's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 1.35 mean?
Labiana Health (XMAD:LAB) has a Capex-to-Operating-Income of 1.35 as of Dec. 2025. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Labiana Health and its competitors. This is 18% below median its historical median of 1.65. Over the past decade, Labiana Health's Capex-to-Operating-Income has ranged from 0.60 to 7.29. According to the industry distribution chart, Labiana Health ranks #331 out of 506 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Labiana Health's Capex-to-Operating-Income too high?
Labiana Health's current Capex-to-Operating-Income of 1.35 is 18% below median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 7.29. The Drug Manufacturers industry median Capex-to-Operating-Income is 0.38. Labiana Health's value of 1.35 is 255.3% above this industry median. Based on the distribution chart, Labiana Health ranks #331 out of 506 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Labiana Health has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Capex-to-Operating-Income compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #331 out of 506 companies for Capex-to-Operating-Income. This places Labiana Health in the lower half of its industry. The industry median Capex-to-Operating-Income is 0.38. Labiana Health's value of 1.35 is 255.3% above this benchmark. Historically, Labiana Health's own Capex-to-Operating-Income has ranged from 0.60 to 7.29 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 0.38, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Drug Manufacturers company?
The median Capex-to-Operating-Income among Drug Manufacturers companies is 0.38, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Capex-to-Operating-Income of 1.35 is 255.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Income is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Capex-to-Operating-Income is 1.35, which is 18% below median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.62, compared to a current price of €6.30 — trading 74% above its estimated fair value. The current Capex-to-Operating-Income is 1.35, which is 18% below median its 10-year median of 1.65 and 255.3% above the Drug Manufacturers industry median of 0.38. Labiana Health's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Capex-to-Operating-Income is 1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.30 is trading 74% above its estimated GF Value™ of €3.62.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Capex-to-Operating-Income: 1.35 (18% below median its 10-year median of 1.65)
GF Value™: €3.62 vs. price of €6.30 (74% above fair value)
Industry Position: 255.3% above the Drug Manufacturers median (#331 of 506)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
54GF Score
Get the complete analysis for XMAD:LAB
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
